Revive Therapeutics CSE: RVV | OTC: RVVTF Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly. Revive Therapeutics$0.51005.15%$0.0200 Latest News Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application March 19, 2021 Revive Therapeutics Acquires Unique Psilocybin Assets February 17, 2021 Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin January 14, 2021 Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study December 31, 2020 Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access December 23, 2020 Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program December 21, 2020 Join our Newsletter Get the latest Company updates delivered to straight to your inbox. Leave this field empty if you're human: